➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Express Scripts
Johnson and Johnson
Moodys
Merck

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

UBRELVY Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Ubrelvy, and when can generic versions of Ubrelvy launch?

Ubrelvy is a drug marketed by Allergan and is included in one NDA. There are five patents protecting this drug.

This drug has eighty-four patent family members in thirty-nine countries.

The generic ingredient in UBRELVY is ubrogepant. One supplier is listed for this compound. Additional details are available on the ubrogepant profile page.

US ANDA Litigation and Generic Entry Outlook for Ubrelvy

Ubrelvy will be eligible for patent challenges on December 23, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 30, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for UBRELVY
International Patents:84
US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Drug Prices: Drug price information for UBRELVY
DailyMed Link:UBRELVY at DailyMed
Drug patent expirations by year for UBRELVY
Drug Prices for UBRELVY

See drug prices for UBRELVY

Generic Entry Opportunity Date for UBRELVY
Generic Entry Date for UBRELVY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for UBRELVY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-001 Dec 23, 2019 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-002 Dec 23, 2019 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-001 Dec 23, 2019 RX Yes No   Start Trial   Start Trial Y   Start Trial
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-002 Dec 23, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-002 Dec 23, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-001 Dec 23, 2019 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Express Scripts
Johnson and Johnson
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.